Mark Bodenrader - Feb 9, 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role: Title: Interim Chief Financial Officer, Vice President, Finance and Chief Accounting Officer
Signature: /s/ Mark Bodenrader
Stock symbol: CERE
Transactions as of: Feb 9, 2022
Transactions value $: $0
Form type: 4
Date filed: 2/11/2022, 05:47 PM
Next filing: Jun 3, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CERE	Stock Option (Right to Buy)	Award	$0	+24.8K		$0.00	24.8K	Feb 9, 2022	Common Stock	24.8K	$30.36	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of this option shall vest and become exercisable on February 9, 2023, with the remainder vesting in thirty-six (36) monthly installments thereafter.

Remarks:

Title: Interim Chief Financial Officer, Vice President, Finance and Chief Accounting Officer